Research dossier
Clinical research on Zeaxanthin
10 trials reviewed across 5 indications.
Strongest evidence
Macular health and AMD risk
Mechanism
Zeaxanthin is one of two carotenoids — alongside lutein — that the retina selectively concentrates in the macula. Zeaxanthin dominates the very center of the fovea, where lutein is more peripheral, and meso-zeaxanthin (converted from lutein in the retina) peaks at the foveal center. The xanthophylls filter high-energy blue light and quench singlet oxygen, protecting photoreceptors from oxidative damage. Macular pigment optical density (MPOD) tracks intake and is the most validated biomarker for retinal xanthophyll status.
AREDS2 (n=4,203) is the only large AMD-progression trial. Its primary intention-to-treat outcome did NOT show overall benefit for L+Z replacement (HR 0.90, p=0.12). A pre-specified subgroup analysis showed meaningful benefit in adults in the lowest baseline dietary L+Z quintile. Smaller trials (MOST n=67, CREST n=121) show that adding meso-zeaxanthin raises central MPOD further but lack hard AMD-endpoint data.
Strongest case: adults with low dietary intake (under ~2 mg/day from food) and at-risk eyes (intermediate AMD, family history, smokers/former smokers, advanced age). For adults eating kale, spinach, eggs, and peppers regularly, AREDS2 subgroup data suggest minimal incremental benefit.
Trials cited
AREDS2 — lutein + zeaxanthin and AMD progression (primary outcome)
Null · RCT
AREDS2 Research Group / Chew et al., 2013, JAMAn=4203AREDS2 randomized 4,203 high-risk AMD adults. The primary intention-to-treat comparison of lutein + zeaxanthin vs placebo (on the original AREDS background) did not reach statistical significance for slowing progression to advanced AMD (HR 0.90, p=0.12). The headline 'L+Z prevents AMD' read of AREDS2 is not what the primary endpoint showed.
Supplement marketing routinely reports AREDS2 as a clean positive. It was not. The primary endpoint was null. The practical importance of the trial was that L+Z matched the original beta-carotene formula on outcomes while removing the lung-cancer signal beta-carotene carried for former smokers.
AREDS2 subgroup analysis — low-baseline-intake quintile
mixed · RCT
Chew et al., 2014, JAMA Ophthalmology (secondary AREDS2 analysis)n=4203Pre-specified subgroup analysis showed adults in the lowest quintile of baseline dietary L+Z intake had a meaningful reduction in progression to advanced AMD with L+Z supplementation (HR ~0.74) — but the highest-intake quintile saw essentially no benefit. The clinical signal is concentrated in adults who don't eat their greens.
Subgroup analyses are hypothesis-generating, not confirmatory. The headline 'lutein/zeaxanthin reduces AMD by X%' framing collapses without the baseline-intake stratification. Adults who already eat kale, spinach, peppers, and egg yolks regularly should not expect this magnitude of effect.
Bone & Landrum — macular pigment optical density methodology
positive · Observational
Bone et al., 1997, Investigative Ophthalmology & Visual Sciencen=87Foundational autopsy + psychophysical work establishing that zeaxanthin and meso-zeaxanthin dominate the very center of the macula while lutein concentrates more peripherally. Anchored the methodology for measuring macular pigment optical density (MPOD) — the proxy used in nearly all subsequent supplementation trials.
Methodological, not interventional. Establishes the biomarker; does not test the intervention.
CREST — central retinal enrichment with meso-zeaxanthin formulation
positive · RCT
Nolan et al., 2016, Investigative Ophthalmology & Visual Sciencen=121Adding meso-zeaxanthin to the AREDS2-style lutein + zeaxanthin combination produced higher central MPOD and modestly better contrast sensitivity at 12 months versus L+Z alone. The strongest evidence to date that meso-zeaxanthin supplementation contributes beyond what lutein conversion provides endogenously.
Single research group; replication outside the Waterford / Nolan team remains limited. Contrast sensitivity gains are statistically detectable but practically modest in adults with normal baseline vision.
MOST — meso-zeaxanthin in early AMD
positive · RCT
Akuffo et al., 2015, British Journal of Ophthalmology (Meso-zeaxanthin Ocular Supplementation Trial)n=67MOST showed that the meso-zeaxanthin-inclusive formulation raised MPOD and improved contrast sensitivity in adults with early AMD over 12 months. Supports the rationale for including all three macular xanthophylls in AMD-targeted formulations.
Small sample (n=67) and single research group. The translation from raised MPOD and contrast sensitivity to slowed AMD progression has not been demonstrated in trials of this size.
Visual performance — glare, contrast, photostress
Mechanism
Higher macular pigment density absorbs high-energy short-wavelength light before it scatters in the photoreceptor layer. The proposed functional benefit is faster recovery from bright-light insult (photostress), reduced glare disability, and better contrast at the foveal center.
Multiple small RCTs (Hammond 2014, Stringham 2017, Yao 2018) — predominantly Kemin/OmniActive-funded — show measurable improvements in contrast sensitivity, photostress recovery, and glare disability with 10–24 mg/day of L + zeaxanthin formulations over 6–12 months. Effect sizes are statistically detectable but practically modest, and the literature is concentrated in one research group.
Most relevant for adults with sustained near-field screen exposure or self-reported glare difficulty. Healthy young adults with normal contrast sensitivity gain less than the 'blue-light protection' marketing implies.
Stringham — macular carotenoids and visual performance
positive · RCT
Stringham et al., 2017, Foodsn=48Industry-fundedHeavy screen users on 24 mg/day Lutemax 2020 showed statistically significant improvements in contrast sensitivity, glare disability, and photostress recovery time vs placebo. Self-reported eye strain and headache frequency dropped modestly. The 'blue-light protection' marketing comes from this kind of trial — but the effect sizes are clinically modest.
Industry-funded by OmniActive (the Lutemax 2020 manufacturer). 24 mg/day is well above the AREDS2 dose; the supplement-industry leap from 'helps heavy screen users' to 'everyone needs blue-light protection' is not supported.
Hammond — L+Z and visual range / glare disability
positive · RCT
Hammond et al., 2014, Investigative Ophthalmology & Visual Sciencen=115Industry-fundedOne year of AREDS2-dose L+Z in healthy young adults raised MPOD and improved photostress recovery, disability glare thresholds, and chromatic contrast sensitivity vs placebo. The visual-performance signal is real and replicates across multiple trials from the Hammond/Stringham group.
Same lab group dominates the young-adult visual-performance literature for L+Z; independent replication is thinner than the headline reports imply. Effect magnitudes in absolute terms are modest.
Yao — Lutemax 2020 bioavailability
positive · RCT
Yao et al., 2018, Nutrition Researchn=59Industry-fundedTwelve weeks of 12 mg/day Lutemax 2020 raised serum and macular pigment levels reliably across all age strata. Confirms that branded L+Z formulations do what they say at the biomarker level. Does not establish a clinical visual or cognitive endpoint benefit.
Industry-funded by OmniActive. Biomarker improvements (serum, MPOD) do not automatically translate into improvements on hard clinical endpoints in healthy adults — this is the pattern that runs through nearly all the visual-performance and cognition trials.
Cognition and brain xanthophyll status
Mechanism
Lutein and zeaxanthin cross the blood-brain barrier and concentrate in the frontal and occipital cortex. Autopsy and serum-cognition observational work (Johnson, Mewborn) links higher brain xanthophyll content with better cognitive performance in older adults. MPOD functions as a non-invasive proxy for brain xanthophyll status.
The cognition RCT base for L + zeaxanthin is small (Renzi-Hammond 2017 in young adults; Lindbergh / Hammond trials in older adults — see the lutein dossier for parallel data). Effect sizes are modest and most trials are industry-funded by Kemin or OmniActive. The mechanism is plausible; the clinical-endpoint claim outruns the data for healthy adults seeking cognitive enhancement.
Most credible in older adults with subjective cognitive complaints and low baseline dietary xanthophyll intake. The marketing claim that L+Z is a 'cognitive enhancer for healthy young professionals' is not supported by independent-lab replication.
Renzi-Hammond — L+Z and cognition in young adults
positive · RCT
Renzi-Hammond et al., 2017, Nutrientsn=51Industry-fundedOne year of AREDS2-dose L+Z in healthy young adults produced modest improvements in spatial memory, reasoning, and complex attention versus placebo. MPOD rose in supplemented participants. The signal is consistent with the brain-xanthophyll mechanism but the effect sizes are small.
Industry-funded; same research group as most of the L+Z cognition literature. The marketing leap from 'modest cognitive gains over a year' to 'L+Z for cognitive enhancement' outruns the data — particularly for healthy young adults who are not the population with the biggest plausible gain.
Skin photoprotection
Mechanism
Zeaxanthin and lutein deposit in skin and act as lipid-phase antioxidants against UV-induced lipid peroxidation — the same mechanism by which they protect retinal tissue. They are not sunscreens; they reduce oxidative load downstream of UV exposure rather than blocking the UV itself.
The clinical literature here is thin and largely belongs to the lutein dossier (Palombo 2007 used a combined L + zeaxanthin oral preparation). Mechanism is consistent with antioxidant carotenoid biology; the controlled-trial evidence for zeaxanthin-specific photoprotection is supportive, not foundational.
Supportive evidence only. Useful as one part of a broader skin-antioxidant approach; never a replacement for sunscreen or topical photoprotection.
Filling a widespread dietary intake gap
Mechanism
Zeaxanthin is not classified as essential — there is no RDA. But average US dietary intake of lutein + zeaxanthin combined is approximately 1–2 mg/day, well below the 6+ mg associated with adequate macular pigment density in observational cohorts. People who don't eat eggs, leafy greens, corn, or orange peppers regularly are functionally low.
The strongest 'general health' case for zeaxanthin is the same as for vitamin K2 or lutein: closing a real dietary gap, not chasing a transformative effect. The AREDS2 subgroup data make this honest — the people most likely to benefit are the ones with the lowest baseline intake.
Most relevant for adults who do not regularly consume eggs, dark leafy greens, peppers, and corn. Adults with green-vegetable-rich diets gain less than the supplement labels imply.
AREDS2 subgroup analysis — low-baseline-intake quintile
mixed · RCT
Chew et al., 2014, JAMA Ophthalmology (secondary AREDS2 analysis)n=4203Pre-specified subgroup analysis showed adults in the lowest quintile of baseline dietary L+Z intake had a meaningful reduction in progression to advanced AMD with L+Z supplementation (HR ~0.74) — but the highest-intake quintile saw essentially no benefit. The clinical signal is concentrated in adults who don't eat their greens.
Subgroup analyses are hypothesis-generating, not confirmatory. The headline 'lutein/zeaxanthin reduces AMD by X%' framing collapses without the baseline-intake stratification. Adults who already eat kale, spinach, peppers, and egg yolks regularly should not expect this magnitude of effect.
Yao — Lutemax 2020 bioavailability
positive · RCT
Yao et al., 2018, Nutrition Researchn=59Industry-fundedTwelve weeks of 12 mg/day Lutemax 2020 raised serum and macular pigment levels reliably across all age strata. Confirms that branded L+Z formulations do what they say at the biomarker level. Does not establish a clinical visual or cognitive endpoint benefit.
Industry-funded by OmniActive. Biomarker improvements (serum, MPOD) do not automatically translate into improvements on hard clinical endpoints in healthy adults — this is the pattern that runs through nearly all the visual-performance and cognition trials.
Honest-evidence ledger — 1 trial that didn’t move the needle
Surfacing failed trials alongside the positive evidence. Leaving them out would be marketing, not science.
CARET / ATBC — high-dose beta-carotene in smokers (historical context)
negative · RCT
Omenn et al., 1996, NEJM (CARET); ATBC Cancer Prevention Study Group, 1994, NEJMn=47000CARET (n≈18,000) and ATBC (n≈29,000) independently found that high-dose beta-carotene supplementation increased lung cancer incidence and mortality in smokers. CARET was stopped early for harm. These trials are why AREDS2 substituted lutein + zeaxanthin for the original AREDS beta-carotene component — not because L+Z is more effective, but because beta-carotene is dangerous in this population.
Included here as historical context, not as zeaxanthin-specific evidence. Lutein and zeaxanthin themselves do not carry the lung cancer signal that high-dose beta-carotene does. The trials are the reason AREDS2 was structured the way it was.
2 forms of Zeaxanthin compared
FloraGLO® / OPTISHARP® (Kemin)
FloraGLO lutein + OPTISHARP zeaxanthin
Well absorbed when taken with fat; the form combination used in AREDS2
Best forAMD risk reduction in adults with low dietary intake; macular pigment maintenanceFloraGLO (marigold-derived lutein) plus Kemin's OPTISHARP zeaxanthin is the precise carotenoid combination tested in AREDS2 at 10 mg lutein + 2 mg zeaxanthin. Heavy industry funding through Kemin sits behind most of the supporting clinical literature. Use is most defensible at the AREDS2 dose; sub-AREDS2 amounts in cheap multivitamins are clinically meaningless.
vision2–4 mgLutemax® 2020 (OmniActive)
Lutemax 2020 (lutein + zeaxanthin isomers)
Well absorbed with fat; raises serum and MPOD reliably at 6–24 mg/day
Best forVisual performance (glare, contrast, photostress) and cognitive support in adults with low baseline intakeMarigold-derived combination of lutein, zeaxanthin, and meso-zeaxanthin (5:1:0.5-style ratio). The Lutemax-branded trials by Stringham, Hammond, and Renzi-Hammond drive most of the screen-time / visual-performance / cognition literature. Almost all sponsored by OmniActive — flag accordingly when reading headline effect sizes.
Are you deficient? Symptoms, risk groups, lab tests
Average US dietary intake of lutein + zeaxanthin combined is approximately 1–2 mg/day — well below the 6+ mg associated with adequate macular pigment in observational cohorts and far below the 2 mg/day zeaxanthin used in AREDS2. There is no RDA because zeaxanthin is not classified as essential, but functional dietary insufficiency is the rule in modern Western diets.
Common symptoms
- No specific clinical deficiency syndrome — zeaxanthin is not classified as an essential nutrient
- Low macular pigment optical density (MPOD) on retinal imaging
- Increased susceptibility to glare disability and slower photostress recovery
- Higher long-term risk of advanced AMD in observational cohorts, particularly in low-intake adults
Who is at risk
Adults with low intake of leafy greens, eggs, peppers, and corn
Zeaxanthin food sources are concentrated in egg yolks, corn, orange/yellow peppers, goji berries, spinach, and kale. Diets dominated by ultra-processed foods provide essentially zero. Egg-avoiders are particularly at risk because egg yolk is the most bioavailable dietary source.
Smokers and former smokers
Smoking depletes carotenoid status across the board. Smokers have measurably lower MPOD and higher AMD risk. Important context: this population should specifically avoid the older high-dose beta-carotene 'eye health' formulas — AREDS2 substituted L+Z because of CARET / ATBC.
Adults at risk of AMD
Family history of AMD, intermediate AMD on retinal imaging, advanced age (60+), and low macular pigment density on testing all stack the AMD risk profile. The AREDS2 subgroup data place the strongest evidence-based case for supplementation in this group.
Adults with malabsorption or low-fat diets
Zeaxanthin is fat-soluble and requires dietary fat for absorption. Malabsorption conditions, bariatric surgery, chronic pancreatic insufficiency, and very-low-fat diets all reduce uptake.
Adults with high screen-time exposure
Sustained exposure to short-wavelength light raises retinal oxidative load. Higher MPOD provides functional buffering. The visual-performance trial signal is most consistent in this population — but the effect sizes remain modest.
Lab markers
Macular pigment optical density (MPOD)
MPOD is the gold-standard biomarker for retinal xanthophyll status. Measured non-invasively in specialty optometry / ophthalmology offices via heterochromatic flicker photometry or dual-wavelength autofluorescence. Not a routine screening test; not widely covered by insurance.
Better:Serum lutein + zeaxanthin (less sensitive to retinal status than MPOD)
Side effects and drug interactions
Side effects
Carotenodermia (skin yellow-orange tint)
Uncommon · Typically requires sustained intake well above ~20–30 mg/day combined macular carotenoids
At very high chronic doses, zeaxanthin and related carotenoids can deposit in skin and produce a yellowish or orange tint, most visible in palms and soles. Reversible on dose reduction. Cosmetic only — not a sign of toxicity.
Mild GI upset
Uncommon
Mild nausea or stomach discomfort can occur, particularly when zeaxanthin is taken on an empty stomach. Take with a fat-containing meal to minimize.
Headache
Rare
Rarely reported in trials, usually mild and self-limiting.
Drug interactions
Reduces nutrient status
orlistatcholestyramineezetimibevery-low-fat dietsFat-blockers, bile-acid sequestrants, and very-low-fat diets reduce absorption of fat-soluble carotenoids — including zeaxanthin.
Take zeaxanthin with a fat-containing meal away from these medications. Separate orlistat dosing by at least 2 hours.
Other
beta-carotene supplementshigh-dose vitamin AHigh-dose beta-carotene competes with zeaxanthin (and lutein) for intestinal absorption and can lower xanthophyll status. The historical CARET / ATBC trials established that high-dose beta-carotene increases lung cancer risk in smokers — zeaxanthin does not carry this signal but the carotenoid family interactions matter.
If supplementing for macular health, take the AREDS2-style L+Z combination rather than stacking high-dose beta-carotene on top. Smokers and former smokers should specifically avoid the older high-dose beta-carotene formulas.
Other critical caveats
- AREDS2's primary intention-to-treat outcome was NOT a clean positive for lutein + zeaxanthin. The HR was 0.90 with p=0.12. The benefit signal came from a pre-specified subgroup analysis in adults with the lowest baseline dietary intake. Supplement marketing routinely overstates this; verify the claim against the original 2013 JAMA paper before paying premium prices.
- The visual-performance and cognition literature for L + zeaxanthin is heavily industry-funded — Kemin (FloraGLO / OPTISHARP) and OmniActive (Lutemax 2020) sponsor most of the trials. Independent replication outside the Hammond / Stringham / Nolan research groups is limited. Treat effect-size headlines accordingly.
- Take with a fat-containing meal. Zeaxanthin is fat-soluble; absorption drops significantly without dietary fat. A spinach-and-pepper salad with olive oil works; a fat-free smoothie does not.
- Smokers and former smokers should avoid high-dose beta-carotene 'eye health' formulas (AREDS1 era). The CARET and ATBC trials showed beta-carotene increased lung cancer in smokers, which is why AREDS2 substituted L+Z. Lutein and zeaxanthin themselves do not carry the lung cancer signal — but verify the carotenoid on the label is L+Z, not high-dose beta-carotene.
- Adults who already eat eggs, dark leafy greens, peppers, and corn regularly may gain little incremental benefit. The AREDS2 subgroup that benefited was in the lowest dietary intake quintile. Food first, supplement to fill the gap.
Frequently asked
Is zeaxanthin different from lutein?
Yes, structurally — they are isomers (same atoms, different arrangement). Functionally they overlap heavily and are almost always studied together. Zeaxanthin concentrates at the very center of the macula (fovea); lutein is more peripheral. Meso-zeaxanthin is a third macular xanthophyll, converted from lutein in the retina. AREDS2 used 2 mg zeaxanthin + 10 mg lutein. Pair them — they're clinically inseparable.Did AREDS2 prove that lutein + zeaxanthin prevents AMD?
No — that's the most-misrepresented finding in the supplement aisle. AREDS2's primary intention-to-treat comparison did NOT reach statistical significance (HR 0.90, p=0.12). A pre-specified subgroup analysis showed benefit in adults in the lowest baseline dietary L+Z intake quintile. The trial's most important clinical contribution was replacing beta-carotene safely — beta-carotene caused harm in smokers in CARET and ATBC. AREDS2 was a safety substitution that matched original-formula efficacy, not a proof of incremental benefit.What's the right dose of zeaxanthin?
2 mg/day paired with 10 mg lutein — the AREDS2 dose. Trials testing visual performance and cognition have used up to 4 mg zeaxanthin with 10–20 mg lutein, sometimes with added meso-zeaxanthin. Always take with a meal that contains fat; absorption drops sharply without it. There is no formal upper limit; the practical ceiling is set by carotenodermia at very high chronic intakes.Can I get enough zeaxanthin from food?
Quite possibly, if you eat egg yolks, leafy greens, orange/yellow peppers, corn, and goji berries regularly. One egg yolk contains roughly 0.2–0.3 mg of zeaxanthin in a particularly bioavailable form (the lipid environment helps absorption). Average US intake is about 1–2 mg/day of lutein + zeaxanthin combined because most people don't eat their greens. Food first — the AREDS2 subgroup data make this honest.What is meso-zeaxanthin and do I need it?
Meso-zeaxanthin is the third macular xanthophyll. It concentrates at the very peak of the fovea and is normally formed in the retina by isomerization of lutein. Some supplements include it directly (typically 5–10 mg). The CREST and MOST trials (Nolan group) showed adding meso-zeaxanthin to L+Z raised central MPOD further and modestly improved contrast sensitivity over 12 months. The hard AMD-endpoint data for meso-zeaxanthin specifically is missing. Include it if you can justify the cost; the AREDS2-only formulation is the better-evidenced baseline.Is zeaxanthin safe for smokers?
Yes. Zeaxanthin and lutein themselves do not have a lung cancer signal. The carotenoid smokers should specifically avoid in high doses is beta-carotene — CARET and ATBC found it increased lung cancer in this population. AREDS2 specifically replaced beta-carotene with L+Z because of those trials. If you take an 'eye health' formula, check that the carotenoid is L+Z (or AREDS2-style), not high-dose beta-carotene.Can I take too much zeaxanthin?
Toxicity has not been established. Carotenodermia (harmless yellow-orange skin tint) is the only documented effect of very high chronic intake of combined macular carotenoids and resolves when the dose drops. There is no defined upper limit. The practical ceiling is set by cost and absorption — 4 mg/day of zeaxanthin (alongside 10–20 mg/day of lutein) is more than enough for any documented benefit.
References
- 01AREDS2 Research Group — Lutein + Zeaxanthin and Omega-3 Fatty Acids for AMD (JAMA 2013, primary outcome)
- 02Chew et al., 2014, JAMA Ophthalmology — AREDS2 secondary analyses by baseline L+Z intake
- 03National Eye Institute — AREDS / AREDS2 Clinical Trials patient resource
- 04NIH Office of Dietary Supplements — Carotenoids fact sheet
- 05American Academy of Ophthalmology — AREDS2 supplements and AMD
- 06Omenn et al., 1996, NEJM — CARET trial (beta-carotene and lung cancer in smokers; AREDS2 context)
Last reviewed2026-05-22